PAH Pathways Counselors

PAH Pathways Interactive Resource Locator

PAH Pathways offers a wealth of resources including one-on-one support from PAH Pathways counselors in your area.
Learn more »

Simplifying every step of patient management

Patients on Tracleer or Ventavis Inhalation Solution face many practical concerns. How will they ensure that their medication is delivered when they need it? How will they pay for therapy? How can they understand their insurance coverage? Where can they turn for additional support?

Fortunately, PAH Pathways is staffed by a team of counselors trained in PAH. Our counselors make your job easier by providing valuable enrollment, reimbursement information, and patient education support so that you can concentrate on the important job of managing your patients.

Simplified enrollment
A clear path to insurance coverage information and financial assistance programs
Unique online patient management programs
Extensive education and support for every step of your patient's journey

To speak to a PAH Pathways counselor in your region, call:
1-866-ACTELION (228-3546)
Monday through Friday, 9 AM-8 PM (ET)/6 AM-5 PM (PT)

Tracleer is indicated for the treatment of pulmonary arterial hypertension (PAH) in patients with WHO Class II-IV symptoms, to improve exercise ability and decrease the rate of clinical worsening. Patients with WHO Class II symptoms showed reduction in the rate of clinical deterioration and a trend for improvement in walk distance. Physicians should consider whether these potential benefits are sufficient to offset the risk of liver injury in WHO Class II patients, which may preclude future use as their disease progresses.

Tracleer Important Safety Information

Because of the associated risks, Tracleer may be prescribed only through the Tracleer Access Program. Potential for serious liver injury (including, after prolonged treatment, rare cases of liver failure and unexplained hepatic cirrhosis in a setting of close monitoring) – Liver monitoring of all patients is essential prior to initiation of treatment and monthly thereafter. High potential for major birth defects – Pregnancy must be excluded and prevented through the use of reliable forms of birth control; monthly pregnancy tests should be obtained.

Contraindicated for use with cyclosporine A and glyburide.

Please see full Prescribing Information, including BOXED WARNING and Medication Guide.

Ventavis is indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms.

Important safety information about Ventavis:

In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. Ventavis should not be initiated in patients with systolic blood pressure less than 85 mm Hg. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension.

Please see full Prescribing Information